rs80338672
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000158.4(GBE1):c.1543C>T(p.Arg515Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000808 in 1,608,504 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000158.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBE1 | NM_000158.4 | c.1543C>T | p.Arg515Cys | missense_variant | 12/16 | ENST00000429644.7 | NP_000149.4 | |
GBE1 | XR_007095662.1 | n.1671C>T | non_coding_transcript_exon_variant | 12/15 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBE1 | ENST00000429644.7 | c.1543C>T | p.Arg515Cys | missense_variant | 12/16 | 1 | NM_000158.4 | ENSP00000410833 | P1 | |
GBE1 | ENST00000489715.1 | c.1420C>T | p.Arg474Cys | missense_variant | 12/16 | 2 | ENSP00000419638 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 151886Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000370 AC: 9AN: 243364Hom.: 0 AF XY: 0.0000378 AC XY: 5AN XY: 132170
GnomAD4 exome AF: 0.00000824 AC: 12AN: 1456618Hom.: 0 Cov.: 31 AF XY: 0.00000828 AC XY: 6AN XY: 724450
GnomAD4 genome AF: 0.00000658 AC: 1AN: 151886Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74162
ClinVar
Submissions by phenotype
Glycogen storage disease, type IV Pathogenic:3Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 24, 2024 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Mar 30, 2023 | This sequence change is predicted to replace arginine with cysteine at codon 515 of the GBE1 protein, p.(Arg515Cys). The arginine residue is highly conserved (100 vertebrates, UCSC), and is located within a helical region in the catalytic domain (PMID: 26199317). There is a large physicochemical difference between arginine and cysteine. The variant is present in a large population cohort at a frequency of 0.004%, which is consistent with recessive disease (rs80338672, 9/243,364 alleles, 0 homozygotes in gnomAD v2.1). It has been identified compound heterozygous with a second pathogenic allele or suspected compound heterozygous in cases with the fatal perinatal neuromuscular form or infantile classic hepatic phenotype of glycogen storage disorder type IV. Further, there was biochemical confirmation of the diagnosis in the cases with the classic hepatic phenotype, through the measurement of branching enzyme activity in patient fibroblasts (PMID: 8613547, 20058079, 26147564). Reduced enzymatic activity of the variant has also been demonstrated in in vitro functional studies (PMID: 8613547). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (7/7 algorithms). Additionally, a different missense change (p.Arg515His) at the same position, determined to be pathogenic has been identified in adult polyglucosan body disease (PMID: 10762170). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as LIKELY PATHOGENIC. Following criteria are met: PM2, PM3, PM5, PS3_Supporting, PP3, PP4. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 08, 2021 | Variant summary: GBE1 c.1543C>T (p.Arg515Cys) results in a non-conservative amino acid change located in the Glycosyl hydrolase, family 13, catalytic domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.7e-05 in 243364 control chromosomes. c.1543C>T has been reported in the literature in individuals affected with Glycogen Storage Disease, Type IV (Bao_1996, Li_2010, Farwell_2015). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of normal activity (Bao_1996). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as likely pathogenic. In addition, p.R515H has been reported to associate with the disease too. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Glycogen storage disease IV, classic hepatic Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 15, 1996 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 30, 2013 | - - |
Glycogen storage disease, type IV;C1856301:Glycogen storage disease IV, classic hepatic Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 05, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 515 of the GBE1 protein (p.Arg515Cys). This variant is present in population databases (rs80338672, gnomAD 0.01%). This missense change has been observed in individual(s) with glycogen storage disease, also known as polyglucosan body myopathy (PMID: 8613547, 11949934). ClinVar contains an entry for this variant (Variation ID: 2779). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GBE1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects GBE1 function (PMID: 8613547). This variant disrupts the p.Arg515 amino acid residue in GBE1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10762170, 24248152). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at